Pegvisomant Patent Expiration
Pegvisomant is used for treating acromegaly in patients who have not responded well to surgery, radiation therapy, or medical therapies. It was first introduced by Pharmacia And Upjohn Co
Pegvisomant Patents
Given below is the list of patents protecting Pegvisomant, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Somavert | US5849535 | Human growth hormone variants |
Mar 25, 2017
(Expired) | Pharmacia And Upjohn |
Somavert | US5849535 | Human growth hormone variants |
Mar 25, 2017
(Expired) | Pharmacia |
Somavert | US6057292 | Method for inhibiting growth hormone action |
Sep 21, 2015
(Expired) | Pharmacia |
Somavert | US6057292 | Method for inhibiting growth hormone action |
Sep 21, 2015
(Expired) | Pharmacia And Upjohn |
Pegvisomant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List